Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (1003)	8/29/2003 7:42:10 PM
From: SemiBull	Read Replies (1) \| Respond to of 1139

ICOS to Participate in Two Upcoming Healthcare Conferences Friday August 29, 8:30 am ET BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 29, 2003--ICOS Corporation (Nasdaq:ICOS - News) announced today that it will participate in the Bear Stearns Healthcare Conference on September 8, 2003, and the UBS Global Life Sciences Conference on September 23, 2003. Bear Stearns Healthcare Conference Presentation Date: September 8, 2003 Times: 2:00 p.m. EDT Speaker: Paul N. Clark, Chairman, CEO and President A webcast of this ICOS presentation will be available in real-time and a replay will be available through September 15, 2003. The webcast can be accessed through the ICOS website, www.icos.com, Investor -- Events section. UBS Global Life Sciences Conference Presentation Date: September 23, 2003 Time: 8:30 a.m. EDT Speaker: Michael Stein, Vice President and Chief Financial Officer A webcast of this ICOS presentation will be available in real-time and a replay will be available through September 30, 2003. The webcast can be accessed through the ICOS website, www.icos.com, Investor -- Events section. Additional information on ICOS, including past press releases, is available at www.icos.com. ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, and sepsis and other inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing opportunities to market breakthrough products. The forward-looking statements contained in this press release represent the Company's judgment as of the date of this release. ICOS undertakes no obligation to publicly update any forward-looking statements. The biotechnology and pharmaceutical businesses are risky and there can be no assurance that any particular product candidate will progress and become a commercial product. Contact: ICOS Corporation, Bothell Lacy Fitzpatrick, 425-415-2207 Source: ICOS Corporation